Back to top
more

ImmunityBio (IBRX)

(Delayed Data from NSDQ)

$2.41 USD

2.41
7,914,985

+0.03 (1.05%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.41 +0.01 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

by Zacks Equity Research

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

Zacks Equity Research

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of -25% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK

by Zacks Equity Research

ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.

Zacks Equity Research

J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug

by Zacks Equity Research

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.

Zacks Equity Research

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of 22.22% and 39.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 10.71% and 63.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -14.29% and 21.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -5.77% and 11.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of 8.75% and 2.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Shrabana Mukherjee headshot

2 Stocks to Watch After New Analyst Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as EGBN and IBRX indicates the potential for significant price appreciation in the near term.

Zacks Equity Research

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -62.50% and 72.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Company News for Aug 13, 2024

by Zacks Equity Research

Companies in The News Are: GOLD,MNDY,IBRX,RNA

Zacks Equity Research

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix (QTRX) delivered earnings and revenue surprises of -8.70% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 33.33% and 4.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 5.71% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 37.50% and 32.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?